MOJ
eISSN: 2374-6939
Submit manuscript...
Short Communication Volume 18 Issue 5
Treatment outcomes of tofacitinib in rheumatoid arthritis patients previously on methotrexate in a hospital in Kisumu, Western Kenya
Charles Omondi, , Sanjeev Parma,
Received: October 10, 2026 | Published: October 22, 2026
Citation: Omondi C, Parma S. Treatment outcomes of tofacitinib in rheumatoid arthritis patients previously on methotrexate in a hospital in Kisumu, Western Kenya. MOJ Orthop Rheumatol. 2026;18(5):174-176. DOI: 10.15406/mojor.2026.18.00761
Abstract
Introduction: JAK inhibitors are a newer class of drugs for treating Rheumatoid arthritis and they are currently in use in many continents. Their use in sub-Saharan Africa has rarely been documented in referred journals. Objective: To assess and document the clinical outcomes of Rheumatoid arthritis patients treated with tofacitinib after methotrexate in a hospital in Kisumu, Western Kenya. Methodology: This was a retrospective chart review of patients who had previous been treated with methotrexate based combinations with poor outcomes or intolerance, and had completed at least 6 months of tofacitinib treatment. CDAI scores were done at baseline and at 6 months post-treatment. Treatment side effects were evaluated from the data and analysed. Results: There was significant improvement of CDAI scores after 6 months treatment with tofacitinib with minimal serious infections. Conclusion: Tofacitinib is efficacious in African populations.
Keywords: methotrexate, tofacitinib, treatment failure, improvement, infections
©2026 Omondi, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.
Citations
Media Partner & Supporters
